Oral Antibiotics for Acne: Basic Concepts & Practical Considerations

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

Drs. Mahmoud Ghannoum, Emmy Graber & Adam Friedman

Antibiotic use for inflammatory skin diseases is a staple in dermatology. Like milk is the answer to a chunky peanut butter sandwich (just go with me on this), so too have tetracycline antibiotics been married to the management of Acne Vulgaris. And just as that delicious combo comes at a fattening cost, the overuse and abuse of antibiotics has an impressive and significant impact both on the risk for antimicrobial resistance and gut/cutaneous dysbiosis.

To get to the piloseabeous unit of the matter, JDD Podcast host Dr. Adam Friedman picks the brains of AAA experts Dr. Emmy Graber and Dr. Mahmoud Ghannoum to provide a true bench to bedside review of the issues at hand. Pop in to learn how to interpret minimum inhibitory concentrations (MIC), understand newly identified information on dysbiosis (including impaired microbiota), and appreciate the implications of indiscriminate use of broad-spectrum antibiotics in acne therapy including the clinical consequence of antibiotic resistance and benefits of narrow-spectrum agents.

Listen Now

Learning Objectives

Upon completion of this podcast participants should be able to:

Describe the differences between antibiotic types and their use in acne therapy
Discuss interpretation and measurement of MIC, resistance and dysbiosis
Summarize the clinical implications of antibiotic resistance
Summarize the clinical implications of dysbiosis

This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.

Disclosures

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

Mahmoud Ghannoum, PhD – Grant/Research: Almirall. Consultant: Almirall.

Emmy M. Graber, MD, MBA – Grant/Research: Ortho Dermatologics. Consultant: Almirall, Digital Diagnostics, Sebacia, SolGel. Speakers’ Bureau: Almirall

APP-solutely Essential: Putting Corticosteroid Stewardship Into Practice

Mikaela Sonis | Featured Articles, Featured Podcast, Global Steroidal Stewardship, Latest News, Podcast, Podcast Highlights | No Comments

Guest: Douglas DiRuggiero Corticosteroids remain one of dermatology’s most reliable workhorses, but good stewardship isn’t about putting the horse out to pasture. It’s about knowing when to ride, when to…

Shots, Shots, Shots: Is There Such a Thing as One Too Many?

Mikaela Sonis | Featured Articles, Featured Podcast, Latest News, Podcast, Podcast Highlights | No Comments

Guest: Dr. Joseph Bax Corticosteroid injections are everywhere in musculoskeletal medicine. Epidurals, joints, facets, bursae: when inflammation and pain are the targets, steroids have long been one of the sharpest…

F around and Find Out: Failing Forward, IL-17F in Focus, and Finding New Treatment Paradigms and Friendships through Industry Collaborations

Mikaela Sonis | Featured Articles, Featured Podcast, Latest News, Podcast, Podcast Highlights | No Comments

Guest: Dr. Tae Oh For too long, the therapeutic ladder in hidradenitis suppurativa has often looked less like a ladder and more like an uneven mound: try this, fail that,…